Eli Lilly and Company (LLY) Stock Analysis
Over the past 10 years, Eli Lilly and (LLY) earnings per share (EPS) grew 26.6% a year, revenue grew 12.6% a year and free cash flow grew 21.0% a year, with an average return on invested capital (ROIC) of 18.1%. LLY stock trades at $1,248.28, a P/E of 41.8, below its historical average of 64.5. Analysts' average 12-month price target is $1,345.80 (+7.8%).
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications.
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | 8.4% | 38.0% | 86.7% | A- |
| EPS GrowthEPS | 26.6% | 29.0% | 94.6% | A+ |
| Revenue GrowthRevenue | 12.6% | 21.6% | 49.6% | A+ |
| Cash Flow GrowthCash Flow | 21.0% | 14.9% | 40048.0% | A+ |
| ROICROIC | 18.1% | 23.9% | 30.2% | A+ |
Exhibit B Valuation Ledger
- Current EPS
- $29.89
- Historical Avg P/E
- 64.5
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $13.18 | $12.72 | $11.02 | $9.51 | $2.72 | $5.90 | $9.42 | $11.21 | $11.93 | $15.70 | $29.55 | $37.91 | |
| Basic EPSEPS | $2.18 | $2.49 | -$0.19 | $3.14 | $8.69 | $6.47 | $5.85 | $6.57 | $5.83 | $11.76 | $23.07 | $29.89 | |
| RevenueRevenue | $19,958,700,000 | $21,222,100,000 | $19,973,800,000 | $21,493,300,000 | $22,319,500,000 | $24,539,800,000 | $28,318,400,000 | $28,541,400,000 | $34,124,100,000 | $45,043,000,000 | $65,179,000,000 | $79,665,800,000 | |
| Free Cash FlowCash Flow | $1,338,400,000 | $3,759,000,000 | $3,452,000,000 | $2,506,300,000 | $3,483,100,000 | $4,470,500,000 | $5,387,500,000 | $4,600,400,000 | $-3,152,000,000 | $3,760,100,000 | $8,972,000,000 | $20,053,900,000 | |
| ROIC (%)ROIC | 11.3% | 10.6% | -0.5% | 15.6% | 18.2% | 18.1% | 20.4% | 23.5% | 19.8% | 25.7% | 30.2% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
45 firms rate it — 33 buy, 9 hold, 3 sell · Most recent Oct 2026
LLY Stock FAQ
What is LLY's stock price target?
The average 12-month analyst price target for LLY is $1,345.80, with a range of $940.00 to $1,500.00. That is +7.8% from the current price of $1,248.28.
Do analysts rate LLY a buy?
Most rate it a buy. Of 45 firms covering Eli Lilly and, the ratings are 33 buy or strong buy, 9 hold and 3 sell or strong sell.
How fast is Eli Lilly and growing?
Annual growth rates for LLY. EPS: 26.6% over 10 years, 29.0% over 5 years, 94.6% over 1 year. Revenue: 12.6% over 10 years, 21.6% over 5 years, 49.6% over 1 year. Free cash flow: 21.0% over 10 years, 14.9% over 5 years, 40048.0% over 1 year. Book value per share: 8.4% over 10 years, 38.0% over 5 years, 86.7% over 1 year.
What is LLY's ROIC?
Eli Lilly and's return on invested capital (ROIC) was 30.2% in fiscal 2025. Its 10-year average ROIC is 18.1%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is LLY's P/E ratio?
LLY's current P/E ratio is 41.8, compared with a historical average of 64.5. Trailing earnings per share are $29.89.
What is Eli Lilly and's market cap and stock price?
LLY last traded at $1,248.28 as of October 19, 2026. Its 52-week range is $793.82 to $1,292.65. Eli Lilly and has a market cap of $1.18T.
Exhibit D Related Coverage
Similar Stocks
Data as of October 19, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.